Payment overview · 2025
General Payments
$19.53
1 reported records · 1 companies
Healthcare provider profile · identity verified
Kaley Miller
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · CENTER VALLEY, PA · NPI 1538617105
Verified facts
What the public records show
CMS Open Payments records show Kaley Miller received $19.53 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.53 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $19.53 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 50 |
| Furosemide | Furosemide | 404 | 60 |
| Eliquis | Apixaban | 382 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 49 |
| Gabapentin | Gabapentin | 265 | 40 |
| Potassium Chloride | Potassium Chloride | 246 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 209 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 30 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 154 | 13 |
| Mirtazapine | Mirtazapine | 151 | 24 |
| Sertraline Hcl | Sertraline Hcl | 150 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 29 |
| Lisinopril | Lisinopril | 114 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 103 | 28 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 100 | 90 |
| Oxycodone Hcl | Oxycodone Hcl | 98 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 15 |
| Carvedilol | Carvedilol | 93 | 11 |
| Nystatin | Nystatin | 89 | 29 |
| Prednisone | Prednisone | 87 | 29 |
| Latanoprost | Latanoprost | 86 | 14 |
| Tradjenta | Linagliptin | 86 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 14 |
| Lamotrigine | Lamotrigine | 83 | suppressed |
| Losartan Potassium | Losartan Potassium | 81 | 13 |
| Metformin Hcl | Metformin Hcl | 79 | 13 |
| Simvastatin | Simvastatin | 77 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 17 |
| Methocarbamol | Methocarbamol | 74 | 18 |
| Midodrine Hcl | Midodrine Hcl | 74 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 71 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 14 |
| Trazodone Hcl | Trazodone Hcl | 71 | 14 |
| Levetiracetam | Levetiracetam | 68 | suppressed |
| Torsemide | Torsemide | 68 | 11 |
| Buspirone Hcl | Buspirone Hcl | 67 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 62 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Lorazepam | Lorazepam | 53 | 18 |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Alprazolam | Alprazolam | 47 | suppressed |
| Digoxin | Digoxin | 47 | suppressed |
| Nystop | Nystatin | 46 | 15 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | suppressed |
| Cephalexin | Cephalexin | 43 | 32 |
| Montelukast Sodium | Montelukast Sodium | 43 | suppressed |
| Spironolactone | Spironolactone | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Insulin Lispro | Insulin Lispro | 39 | 11 |
| Budesonide | Budesonide | 36 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 19 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | 11 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Xtampza Er | Oxycodone Myristate | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Sulfasalazine | Sulfasalazine | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Clozapine | Clozapine | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 14 |
| Levemir Flexpen | Insulin Detemir | 20 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | 14 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Tadalafil | Tadalafil | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Arformoterol Tartrate | Arformoterol Tartrate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Lotemax | Loteprednol Etabonate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Yupelri | Revefenacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $19.53 · 1 records | Novo Nordisk Inc | Ozempic, Rybelsus | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error